Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine

Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic ... Biopharmaceuticals, FDA Allergan, Ubrogepant, Migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news